Mesoblast (NASDAQ:MESO) Cut to “Hold” at Jefferies Financial Group

Jefferies Financial Group downgraded shares of Mesoblast (NASDAQ:MESO) from a buy rating to a hold rating in a research note published on Monday, Marketbeat Ratings reports.

Several other research firms have also recently issued reports on MESO. StockNews.com cut shares of Mesoblast from a “hold” rating to a “sell” rating in a research report on Wednesday, September 4th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mesoblast in a report on Thursday, August 29th. Piper Sandler raised their price objective on Mesoblast from $11.00 to $15.00 and gave the stock an “overweight” rating in a report on Thursday, December 19th. Finally, Maxim Group raised Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a research report on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $13.50.

Mesoblast Stock Down 1.2 %

NASDAQ:MESO opened at $17.02 on Monday. Mesoblast has a twelve month low of $1.61 and a twelve month high of $19.15. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21. The stock has a fifty day simple moving average of $10.77 and a 200-day simple moving average of $8.44.

Hedge Funds Weigh In On Mesoblast

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC lifted its holdings in Mesoblast by 46.4% during the third quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock worth $695,000 after buying an additional 26,959 shares during the period. XY Capital Ltd bought a new position in shares of Mesoblast in the 3rd quarter worth $244,000. Signaturefd LLC lifted its stake in shares of Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after purchasing an additional 3,099 shares during the last quarter. Creative Planning bought a new stake in Mesoblast during the third quarter valued at about $147,000. Finally, Perkins Coie Trust Co boosted its position in Mesoblast by 15.0% during the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after purchasing an additional 1,500 shares in the last quarter. 1.43% of the stock is currently owned by institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.